| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
VITAMIN D AND HEALTH IN THE 21ST CENTURY: BONE AND BEYOND |
1 From the Department of Biological Sciences, University of Notre Dame, Notre Dame, IN
ABSTRACT
1
,25-Dihydroxyvitamin D3 [1,25(OH)2D3[, the biologically active form of vitamin D that interacts with the vitamin D receptor (VDR), is a coordinate regulator of proliferation, differentiation, and survival of breast cancer cells. Therefore, vitamin D compounds that bind and activate VDRs offer promise as therapeutic agents for the treatment of established breast cancer. In addition, epidemiologic, clinical, and animal studies suggested that vitamin D status is important for protection against the development of breast cancer. To elucidate potential biological mechanisms through which vitamin D status might be associated with breast cancer risk, basic research studies focused on defining the molecular effects of vitamin D signaling in the normal mammary gland. Both VDR and vitamin D 1-hydroxylase, the enzyme that generates 1,25(OH)2D3, are expressed and dynamically regulated in the normal mammary gland. Furthermore, studies with mice lacking VDRs established that vitamin D participates in negative growth control of the normal mammary gland and that disruption of VDR signaling is associated with abnormal ductal morphologic features, increased incidence of preneoplastic lesions, and accelerated mammary tumor development. These studies support the concept that suboptimal generation of 1,25(OH)2D3 in the mammary gland might sufficiently deregulate VDR-mediated gene expression to sensitize mammary cells to transformation. In light of these observations, studies to define the most appropriate biomarkers of vitamin D status in relation to protection against breast cancer among human subjects are urgently needed.
Key Words: Vitamin D • vitamin D receptor • breast cancer • mammary gland • prevention • vitamin D hydroxylases
This article has been cited by other articles:
|
|
 |
|
  M. Rossi, J. K. McLaughlin, P. Lagiou, C. Bosetti, R. Talamini, L. Lipworth, A. Giacosa, M. Montella, S. Franceschi, E. Negri, et al. Vitamin D intake and breast cancer risk: a case-control study in Italy Ann. Onc., February 1, 2009; 20(2): 374 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Perez-Lopez, P. Chedraui, and J. Haya Review Article: Vitamin D Acquisition and Breast Cancer Risk Reproductive Sciences, January 1, 2009; 16(1): 7 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Sinotte, F. Rousseau, P. Ayotte, E. Dewailly, C. Diorio, Y. Giguere, S. Berube, and J. Brisson Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population Endocr. Relat. Cancer, December 1, 2008; 15(4): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski, K. C. Johnson, C. Kooperberg, M. Pettinger, J. Wactawski-Wende, T. Rohan, J. Rossouw, D. Lane, M. J. O'Sullivan, S. Yasmeen, et al. Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer J Natl Cancer Inst, November 19, 2008; 100(22): 1581 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Blackmore, M. Lesosky, H. Barnett, J. M. Raboud, R. Vieth, and J. A. Knight Vitamin D From Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer Am. J. Epidemiol., October 15, 2008; 168(8): 915 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schernhammer, F. Berrino, V. Krogh, G. Secreto, A. Micheli, E. Venturelli, S. Sieri, C. T. Sempos, A. Cavalleri, H. J. Schunemann, et al. Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, June 18, 2008; 100(12): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Abbas, J. Linseisen, T. Slanger, S. Kropp, E. J. Mutschelknauss, D. Flesch-Janys, and J. Chang-Claude Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study Carcinogenesis, January 1, 2008; 29(1): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Lappe, D. Travers-Gustafson, K M. Davies, R. R Recker, and R. P Heaney Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial Am. J. Clinical Nutrition, June 1, 2007; 85(6): 1586 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, J. E. Manson, I-M. Lee, N. R. Cook, J. E. Buring, and S. M. Zhang Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women Arch Intern Med, May 28, 2007; 167(10): 1050 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shi, J. Guo, D. J. Duff, F. Rahmatpanah, R. Chitima-Matsiga, M. Al-Kuhlani, K. H. Taylor, O. Sjahputera, M. Andreski, J. E. Wooldridge, et al. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma Carcinogenesis, January 1, 2007; 28(1): 60 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M Egan Commentary: Sunlight, vitamin D, and the cancer connection revisited Int. J. Epidemiol., April 1, 2006; 35(2): 227 - 230. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Heaney Nutrition and Chronic Disease Mayo Clin. Proc., March 1, 2006; 81(3): 297 - 299. [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Garland, F. C. Garland, E. D. Gorham, M. Lipkin, H. Newmark, S. B. Mohr, and M. F. Holick The Role of Vitamin D in Cancer Prevention Am J Public Health, February 1, 2006; 96(2): 252 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Breast Cancer Risk J Natl Cancer Inst, July 20, 2005; 97(14): 1084 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Seeman and G. J. Strewler Clinical and Basic Research Papers - December 2004 Selections IBMS BoneKEy, January 1, 2005; 2(1): 1 - 5. [Full Text] [PDF]
|
|
|
|
|
|
D. J Raiten and M. F. Picciano Vitamin D and health in the 21st century: bone and beyond. Executive summary Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1673S - 1677S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
